Rare Medical News
Advertisement
Spotlight On
Hypochondroplasia
Hypochondroplasia is a rare genetic skeletal dysplasia caused primarily by pathogenic variants in the FGFR3 gene, characterized by disproportionate short stature, shortening of the limbs, and variable skeletal abnormalities
Prevalence
2.5–6.7 / 100,000
8,275–22,177
US Estimated
12,825–34,371
EUROPE ESTIMATED
Age of Onset
Unlike Achondroplasia, hypochondroplasia often does not present with striking neonatal findings, which contributes to under-recognition and delayed diagnosis
ICD-10
Q77.8 – Other osteochondrodysplasias with defects of growth of tubular bones and spine
Q77.9 — Osteochondrodysplasia, unspecified
Q77.4 — Achondroplasia
Inheritance pattern
Autosomal dominant
While exact estimates are unclear, most hypochondroplasia cases are thought to result from de novo FGFR3 variants rather than inherited disease.
5 Facts you should know
FACT
Frequently misclassified as idiopathic short stature (ISS) due to subtle clinical signs
Mild, evolving features, including borderline disproportion and normal birth length, mean many patients are worked up as ISS without consideration of skeletal dysplasia.
FACT
Driven by FGFR3-mediated growth plate dysfunction—not GH deficiency
Gain-of-function FGFR3 variants impair endochondral ossification, limiting linear growth despite a normal GH axis.
FACT
Disproportion is often subtle and may emerge over time
Clues such as increased sitting height-to-height ratio and mild limb shortening may not be apparent early but become more evident with longitudinal assessment.
FACT
Genetic testing is central to diagnosis and classification
Phenotypic overlap with ISS and evolving variant interpretation make molecular confirmation essential for diagnostic accuracy.
FACT
5
Targeted therapies are emerging, but clinical thresholds are higher
FGFR3-modulating therapies (e.g., Vosoritide) are established in Achondroplasia, with potential relevance here.
Interest over time
Google searches
Common signs & symptoms
Disproportionate short stature
Stocky build
Macrocephaly
Shortening of the arms and legs
Broad, short hands and feet
Joint laxity
Limited elbow extension
Genu varum
Scoliosis or lumbar lordosis
Spinal stenosis
Recurrent ear infections
Hearing loss
Obstructive sleep apnea
Neurologic or neurocognitive issues
Current treatments
Treatment depends on disease severity and organ involvement.
Growth and Endocrine Management
Longitudinal growth assessment and auxologic monitoring are standard. Growth hormone therapy has been used but remains experimental and off-label, with variable response due to underlying growth plate pathology.
Genetic Evaluation and Counseling
Molecular testing for pathogenic FGFR3 variants is central to diagnosis, family counseling, clinical classification, and specialist referral.
Orthopedic Management
Monitoring and intervention may be required for genu varum, scoliosis, lumbar lordosis, spinal stenosis, or leg length discrepancy. Limb lengthening surgery is an option in select patients, though it remains controversial given its invasive nature.
Neurologic Monitoring
Evaluation may be warranted for seizures, hydrocephalus, neurocognitive impairment, or spinal canal narrowing — complications that are more prevalent in hypochondroplasia than is commonly recognised.
Otolaryngologic and Sleep Management
Assessment and treatment for recurrent otitis media, conductive hearing loss, or obstructive sleep apnea should be part of routine care.
Multidisciplinary and Psychosocial Care
Coordinated care across endocrinology, genetics, orthopedics, neurology, and rehabilitation is essential. Psychosocial support addressing quality of life, emotional wellbeing, and family needs should be integrated into management from diagnosis.
Emerging Targeted Therapies
Therapies targeting dysregulated FGFR3 signaling pathways are being investigated in FGFR3-related skeletal dysplasias, with increasing focus on improving diagnosis and identifying appropriate patients for future therapeutic intervention.
Clinical trials
| Title | Description | Phases | Status | Interventions | More Information |
|---|---|---|---|---|---|
| Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia | The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH | Phase 3 | Enrolling by invitation | Drug: Vosoritide | More Info |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia | ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety, of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib, at one of two doses, of who have completed at least 26 weeks of participation in QED-spon... | Phase 2, Phase 3 | Enrolling by invitation | Drug: infigratinib 0.128 mg/kg/day Drug: infigratinib 0.25 mg/kg/day | More Info |
| A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months | The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period. | Phase 2 | Recruiting | Drug: Vosoritide Drug: Placebo | More Info |
| Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia | The study aims to identify which Syde®-derived digital outcomes are reliable in FGFR3-related Skeletal Dysplasia. This requires to set-up a natural history study to measure limb movements in patients with ACH or HCH. | Recruiting | More Info | ||
| Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy) | This registry is a observational, single-center study designed to collect clinical data on patients with achondroplasia and hypochondroplasia. | Recruiting | Other: Registry | More Info | |
| Prospective Clinical Assessment Study in Children With Hypochondroplasia | This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH). | Recruiting | More Info | ||
| A Multicenter Multinational Observational Study of Children With Hypochondroplasia | This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest. | Recruiting | More Info | ||
| Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH). | Phase 3 | Active | Drug: Vosoritide Drug: Placebo | More Info |
| Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia | Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially addition... | Phase 2 | Enrolling by invitation | Drug: Infigratinib | More Info |